| pubmed-article:20637880 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20637880 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:20637880 | lifeskim:mentions | umls-concept:C0079613 | lld:lifeskim |
| pubmed-article:20637880 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:20637880 | lifeskim:mentions | umls-concept:C1705576 | lld:lifeskim |
| pubmed-article:20637880 | lifeskim:mentions | umls-concept:C1998793 | lld:lifeskim |
| pubmed-article:20637880 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20637880 | pubmed:dateCreated | 2011-2-14 | lld:pubmed |
| pubmed-article:20637880 | pubmed:abstractText | Donor lymphocyte infusions (DLIs) are used for adoptive immunotherapy to prevent or treat relapse and infectious complications after allogeneic hematopoietic stem cell transplantation (HSCT). Unmanipulated DLIs are associated with a risk of graft-versus-host disease (GVHD), probably related to CD8(+) T cell activity. We investigated an automated clinical-scale human-CD4(+)-cell purification method to deplete CD8(+) cells. Twenty-four stem cell recipients received a total of 24 leukapheresis products being enriched for CD4(+) cells using magnetic associated cell sorting (MACS) with an automated device (CliniMACS(®)) before DLIs. MACS resulted in a mean CD4(+) cell count of 16 × 10(6)/kg bw corresponding to 3.4-fold CD4(+) cell enrichment. Mean yield and purity of CD45(+)CD3(+)CD4(+)CD14(-)7AAD(-) were 74% ± 23% and 82% ± 11%, respectively. Median initial dose of DLIs was 1.1 × 10(6) CD4(+)/kg. During a median follow-up of 25 months, 7 (30%) patients experienced GVHD (acute II-IV: n = 4, 17%; acute III-IV: n = 2, 8%; chronic limited: n = 2, 8%; chronic extensive: n = 1, 4%). Thirteen of 21 further evaluable patients (62%) showed measurable clinical response, 2 patients with therapy refractory infectious complications (HSV) showed remarkable immunologic improvement. Automated enrichment of CD4(+) by magnetic cell sorting provides an efficient and rapid method for processing donor lymphocytes. Additional studies should further investigate this approach in terms of efficacy and the risk of GVHD. | lld:pubmed |
| pubmed-article:20637880 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20637880 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20637880 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20637880 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20637880 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20637880 | pubmed:issn | 1523-6536 | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:KrögerNicolau... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:FehseBorisB | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:AyukFrancisF | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:SputtekAndrea... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:StübigThomasT | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:ZanderAxelA | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:LioznovMichae... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:BacherUlrikeU | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:WolschkeChris... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:KlyuchnikovEv... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:AmtsfeldGitta... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:SlesarchukOlg... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:MerleEdeltrau... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:ReckhausMarie... | lld:pubmed |
| pubmed-article:20637880 | pubmed:author | pubmed-author:AdjalléRaissa... | lld:pubmed |
| pubmed-article:20637880 | pubmed:copyrightInfo | Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:20637880 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20637880 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:20637880 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20637880 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20637880 | pubmed:pagination | 374-83 | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:meshHeading | pubmed-meshheading:20637880... | lld:pubmed |
| pubmed-article:20637880 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20637880 | pubmed:articleTitle | Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation. | lld:pubmed |
| pubmed-article:20637880 | pubmed:affiliation | Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. | lld:pubmed |
| pubmed-article:20637880 | pubmed:publicationType | Journal Article | lld:pubmed |
